Simvastatin Nasal Rinses for the Treatment of COVID-19 Mediated Dysomsia
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Olfactory dysfunction (OD) or changes in smell and/or taste is one of the cardinal presenting
symptoms of COVID-19. Despite the prevalence of COVID and resultant OD, the pathophysiology
of COVID-mediated OD is not fully understood, but recent evidence indicates that local
inflammatory and oxidative injury play a major role.
This phase 1 safety trial evaluates the use of simvastatin nasal irrigations for the
management of COVID-mediated OD. We will determine the maximum tolerable dose and evaluate
the safety and tolerability of high-volume simvastatin nasal irrigations in subjects with
persistent COVID-mediated OD.
Each subject will complete bloodwork at baseline and then at the completion of their
participation in the study. During this trial, we will observe olfactory function for each
participant at baseline and completion of this study via the University of Pennsylvania Smell
Identification Test (UPSIT). Investigational product will be shipped directly to the subject
for daily irrigation each day for 4 weeks. Weekly throughout the study for a total of 4
weeks, subjects will complete the Sino-Nasal Outcome Test-22.
The current study would provide the support for Phase II and III clinical trials.
Additionally, the study has applications for other disease processes affecting the sinonasal
cavities.